Connect your AI

Eli Lilly LLY Other Income (Expense)

Other Income (Expense) at other companies

AmgenAMGN

$75M-95.1%

MannkindMNKD

-$14.7M-69.4%

Oruka Therapeutics, Inc.ORKA

$4.61M+12.9%

McKessonMCK

$36M—

ExelixisEXEL

$219K+189%

Lexicon PharmaceuticalsLXRX

$1.54M-30.5%

Other financials

Income statement

Revenue$19.8B+55.5%

Gross profit$16.2B+54.4%

Net income$7.4B+168%

EPS (diluted)$8.26+170%

Balance sheet

Cash & equivalents$5.3B+70.8%

Total debt$43.4B+12.6%

Total equity$31.2B+97.9%

Total assets$116.58B+30.4%

Cash flow

Operating cash flow$5.3B+220%

CapEx$2.3B+54.0%

Free cash flow$3.0B+1,828%

Valuation

Market cap$1.07T+51.7%

Enterprise value$1.11T+49.3%

P/E42.3×-8.8×

P/S14.8×+1.6×

Profitability

Gross margin82.8%+1.1pp

Net margin35%+12.3pp

FCF margin16.4%+8.7pp

Returns & leverage

Return on equity107.6%+29.9pp

Debt / equity1.4×-1.1×

Current ratio1.5×+0.1×

Where this comes from

Reported directly by Eli Lilly in its filing.

Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.

The official record: Eli Lilly’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Eli Lilly's other income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Eli Lilly's other income (expense)?: Eli Lilly (LLY) reported other income (expense) of -$65M in Q1 2026.
How has Eli Lilly's other income (expense) changed year-over-year?: Eli Lilly's other income (expense) increased by 72.8% year-over-year, from -$239M to -$65M.
What is the long-term trend for Eli Lilly's other income (expense)?: Over 3 years (2021 to 2025), Eli Lilly's other income (expense) has grown at a 41.5% compound annual growth rate (CAGR), from -$201.6M to -$571M.
What does other income (expense) mean?: Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.